Loading stock data…
LTRN
$2.51+0.45 (+21.84%)
Market ClosedLast close May 13
Lantern Pharma Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantern Pharma Inc. in the Healthcare sector is trading at $2.51. Wall Street consensus targets $20.00 (2 analysts), implying a +696.8% move over the next 12 months. The stock is currently 56% below its 52-week high of $5.74, remaining 25.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +696.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$2.51
Potential Downside
0%
Whystock Fair Value$2.51
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$20.00+696.8%
Range$15.00 – $25.00
Fundamentals
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.16M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-262.00%
Volume
Today's trading volume
855,256
Recent News
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Lantern Pharma Inc (LTRN) showcases clinical progress and AI-driven innovations while addressing funding needs and operational hurdles.
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating soft tissue sarcomas. According to Lantern Pharma, the ODD designation applies in the United States […]
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
FDA clears Starlight Therapeutics’ IND for Phase Ib/IIa glioblastoma trial
The trial aims to assess the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with recurrent GBM.
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
The trial is designed to assess the safety and efficacy of LP-300 in never-smoker NSCLC patients.